Time to Definitive Health-Related Quality of Life Score Deterioration in Patients with Resectable Metastatic Colorectal Cancer Treated with FOLFOX4 versus Sequential Dose-Dense FOLFOX7 followed by FOLFIRI: The MIROX Randomized Phase III Trial

FOLFOX4 versus sequential dose-dense FOLFOX7 followed by FOLFIRI in patients with resectable metastatic colorectal cancer (MIROX): a pragmatic approach to chemotherapy timing with perioperative or postoperative chemotherapy from an open-label, randomized phase III trial

(2014) M. Hebbar et al.   ANNALS OF ONCOLOGY

Time to health-related quality of life score deterioration as a modality of longitudinal analysis for health-related quality of life studies in oncology: do we need RECIST for quality of life to achieve standardization?

(2013) Amélie Anota et al.   QUALITY OF LIFE RESEARCH

Modifiable and fixed factors predicting quality of life in people with colorectal cancer

(2011) N M Gray et al.   BRITISH JOURNAL OF CANCER

Time to Deterioration in Quality of Life Score as a Modality of Longitudinal Analysis in Patients with Breast Cancer

(2011) Z. Hamidou et al.   ONCOLOGIST

Current treatment for colorectal liver metastases

(2011) Evangelos P Misiakos   WORLD JOURNAL OF GASTROENTEROLOGY

Time until definitive quality of life score deterioration as a means of longitudinal analysis for treatment trials in patients with metastatic pancreatic adenocarcinoma

(2010) Franck Bonnetain et al.   EUROPEAN JOURNAL OF CANCER

Inequity in colorectal cancer treatment and outcomes: a population-based study

(2008) A-E Carsin et al.   BRITISH JOURNAL OF CANCER

Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial

(2008) Bernard Nordlinger et al.   LANCET

Health-Related Quality of Life Impact of Bevacizumab When Combined with Irinotecan, 5-Fluorouracil, and Leucovorin or 5-Fluorouracil and Leucovorin for Metastatic Colorectal Cancer

(2008) F. F. Kabbinavar et al.   ONCOLOGIST